Champions Oncology (CSBR) Total Non-Current Liabilities (2011 - 2026)
Champions Oncology (CSBR) posted quarterly Total Non-Current Liabilities of $22.9 million for Q2 2026, down 19.56% year-over-year from $28.5 million in Q2 2025, and down 4.69% quarter-over-quarter from $24.0 million in Q1 2026.
Champions Oncology (CSBR) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
Champions Oncology's Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $22.9 million for Q2 2026.
- In Q2 2026, Total Non-Current Liabilities fell 19.56% year-over-year to $22.9 million; the TTM figure through Apr 2026 stood at $22.9 million (down 19.56% YoY), while the FY2026 annual figure was $22.9 million, down 19.56% from the prior year.
- Total Non-Current Liabilities for Q2 2026 stood at $22.9 million, down from $24.0 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $29.1 million in Q2 2023, with the low at $22.9 million in Q2 2026.
- The 5-year median for Total Non-Current Liabilities is $26.2 million (2022), against an average of $26.2 million.
- The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities surged 41.92% in 2022, then fell 19.56% in 2026.
- Champions Oncology's Total Non-Current Liabilities stood at $26.6 million in 2022, then advanced by 4.35% to $27.7 million in 2023, then fell by 12.59% to $24.2 million in 2024, then rose by 6.81% to $25.9 million in 2025, then decreased by 11.48% to $22.9 million in 2026.
- Business Quant data shows CSBR's Total Non-Current Liabilities at $22.9 million in Q2 2026, $24.0 million in Q1 2026, and $25.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Champions Oncology | 68.61 Mn | 68.61 Mn | 7.03 Mn | 22.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 22.91 Mn |
| Jan 31, 2026 | 24.04 Mn |
| Oct 31, 2025 | 25.89 Mn |
| Jul 31, 2025 | 26.94 Mn |
| Apr 30, 2025 | 28.49 Mn |
| Jan 31, 2025 | 24.87 Mn |
| Oct 31, 2024 | 24.24 Mn |
| Jul 31, 2024 | 24.90 Mn |
| Apr 30, 2024 | 27.63 Mn |
| Jan 31, 2024 | 28.41 Mn |
| Oct 31, 2023 | 27.73 Mn |
| Jul 31, 2023 | 27.49 Mn |
| Apr 30, 2023 | 29.12 Mn |
| Jan 31, 2023 | 28.50 Mn |
| Oct 31, 2022 | 26.57 Mn |
| Jul 31, 2022 | 24.75 Mn |
| Apr 30, 2022 | 25.89 Mn |
| Jan 31, 2022 | 24.12 Mn |
| Oct 31, 2021 | 20.99 Mn |
| Jul 31, 2021 | 20.33 Mn |